Positive list for medicinal products
A positive list for pharmaceuticals contains pharmaceuticals that are at the expense of an insurance carrier or national health system, e.g. B. the statutory health insurance (GKV) may be prescribed. The selection of drugs is based on therapeutic aspects such as high therapeutic benefit and degree of effectiveness as well as on the basis of economic aspects such as the relationship between costs and benefits.
It can also be stipulated in which cases and to what extent the costs of the drug must be reimbursed. In Switzerland, for example, there are such limitations (so-called limitatio ) that stipulate that only those who are progressively ill or for whom no other treatment is suitable are paid for the drug.
The introduction of a positive list planned in Germany in 1992 in the Health Structure Act has not been implemented despite several attempts. The adoption of a drug positive list law (AMPoLG) was last postponed in 2003.
In most of the Member States of the European Union , including Belgium, Denmark, Finland, France, Greece, Italy, Luxembourg, the Netherlands, Austria, Portugal and Sweden, a positive list is maintained. In Switzerland, there is also a final positive list for medicinal products, the list of specialties . In the United States, many private health insurers have company-specific positive lists.
See also
supporting documents
- ↑ Claudia Schumm-Robustelli: From the hospital to the social welfare office: Cancer can also make people poor in Thurgau. Retrieved December 25, 2019 .
- ↑ Ulrich Schwabe, Dieter Paffrath: Drug Ordinance Report 2003 , Springer, 2003, p. 2.
- ↑ Small question ( Memento of December 21, 2015 in the Internet Archive ) (PDF; 70 kB) by the MPs Dr. Wolf Bauer et al .: Introduction of a drug positive list
- ^ BMG: The glossary on health reform . online ( memento of January 10, 2008 in the Internet Archive ), accessed on April 16, 2007
- ↑ Specialties list Switzerland ( Memento from January 14, 2010 in the Internet Archive )